Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.83 |
| ▸ | FBP1 | P09467 | 2/20 | 0.83 |
| ▸ | KDR | P35968 | 2/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.83 |
| ▸ | AURKA | O14965 | 1/20 | 0.83 |
| ▸ | INSR | P06213 | 1/20 | 0.83 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.83 |
| ▸ | FLT4 | P35916 | 1/20 | 0.83 |
| ▸ | CLK1 | P49759 | 1/20 | 0.83 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.83 |
| ▸ | TEK | Q02763 | 1/20 | 0.83 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.83 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26876 | 1.00 | EGFR (0.83) | EGFRFBP1KDRERBB2AURKA | |
| Water SCHEMBL28549003 | 0.99 | EGFR (0.81) | EGFRFBP1KDRERBB2AURKA | |
| Hydrochloric Acid SCHEMBL28101874 | 0.99 | EGFR (0.81) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL2099106 | 0.91 | EGFR (1.00) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL30505605 | 0.91 | EGFR (1.00) | EGFRFBP1KDRERBB2AURKA | |
| Hydrochloric Acid SCHEMBL27887194 | 0.90 | EGFR (0.98) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL30912752 | 0.89 | FBP1 (0.84) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL26637 | 0.89 | FBP1 (0.84) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL6994526 | 0.89 | EGFR (0.69) | EGFRFBP1KDRERBB2AURKA | |
| SCHEMBL24979 | 0.88 | EGFR (0.68) | EGFRFBP1KDRERBB2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113979954-B | Tinich antitumor drug compound and preparation method and application thereof | 南京友怡医药科技有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-115850248-B | Tinich antitumor drug compound and preparation method and application thereof | 南京友怡医药科技有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-115850248-A | Teninil antitumor drug compound and preparation method and application thereof | 南京友怡医药科技有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-112707869-B | Dacotinib impurity and preparation method thereof | 扬子江药业集团有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-112375043-B | Method for preparing dacomitinib | 江苏食品药品职业技术学院 | 2022-03-08 | — | — | CN | claimed |
| CN-113979954-A | Teninil antitumor drug compound and preparation method and application thereof | 南京友怡医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| CN-118834200-A | 4-Anilino quinazoline compound containing amide structure and application thereof | 辽宁大学 | 2024-10-25 | — | — | CN | disclosed |
| CN-113979954-B | Tinich antitumor drug compound and preparation method and application thereof | 南京友怡医药科技有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-115850248-B | Tinich antitumor drug compound and preparation method and application thereof | 南京友怡医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-114315595-B | Preparation method of carbon-supported iron-based catalyst and application of intermediate synthesis of anticancer inhibitor of carbon-supported iron-based catalyst | 奥锐特药业股份有限公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2023098592-A1 | PREPARATION METHOD FOR CARBON-LOADED IRON-BASED CATALYST AND USE THEREOF IN SYNTHESIS OF INTERMEDIATES OF ANTI-CANCER INHIBITORS | 奥锐特药业股份有限公司 | 2023-06-08 | — | — | WO | disclosed |
| CN-115850248-A | Teninil antitumor drug compound and preparation method and application thereof | 南京友怡医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-114787151-A | Use of quinazoline derivative or salt thereof, or pharmaceutical composition thereof | 正大天晴药业集团股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-112321566-B | EGFR protein degradation agent and anti-tumor application thereof | 上海科技大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-114315595-A | Preparation method of carbon-supported iron-based catalyst and synthesis application of anti-cancer inhibitor intermediate thereof | 湖南大学 | 2022-04-12 | — | — | CN | disclosed |
| CN-112707869-B | Dacotinib impurity and preparation method thereof | 扬子江药业集团有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-113979954-A | Teninil antitumor drug compound and preparation method and application thereof | 南京友怡医药科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | EGFR 2/4885FBP1 2591/4885KDR 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.